{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-090332","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.591528+00:00","generated_at":"2026-05-31T13:12:12.108906+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Design Therapeutics Q2 net loss $11.8M; cash $261M; FA and FECD programs on track","bullets":["Net loss $11.8M for Q2 2024; R&D expense $10.5M, G&A expense $4.5M.","Cash, cash equivalents and marketable securities $261.0M as of June 30; runway into 2029.","FA program DT-216P2 on track to start patient trials in 2025 after GLP studies complete.","FECD program DT-168 to begin Phase 1 in healthy volunteers in 2024; 200-patient observational study ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-090332","json":"https://secwatch.observer/filing/0000950170-24-090332.json","markdown":"https://secwatch.observer/filing/0000950170-24-090332.md","text":"https://secwatch.observer/filing/0000950170-24-090332.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000095017024090332/0000950170-24-090332-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000095017024090332/dsgn-20240805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:12:12.108906+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}